DrugPatentWatch Database Preview
OPTISON Drug Profile
Which patents cover Optison, and when can generic versions of Optison launch?
Optison is a drug marketed by Ge Healthcare and is included in one NDA. There is one patent protecting this drug.
This drug has forty patent family members in twenty-seven countries.
The generic ingredient in OPTISON is albumin human. There are seven drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the albumin human profile page.
Summary for OPTISON
| International Patents: | 40 |
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 33 |
| Clinical Trials: | 16 |
| Formulation / Manufacturing: | see details |
| Drug Prices: | Drug price information for OPTISON |
| DailyMed Link: | OPTISON at DailyMed |
Generic Entry Opportunity Date for OPTISON
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for OPTISON
| Drug Class | Contrast Agent for Ultrasound Imaging |
| Mechanism of Action | Ultrasound Contrast Activity |
US Patents and Regulatory Information for OPTISON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | RX | Yes | Yes | ➤ Sign Up | ➤ Sign Up | Y | ➤ Sign Up | |||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for OPTISON
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ➤ Sign Up | ➤ Sign Up |
| Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ➤ Sign Up | ➤ Sign Up |
| Ge Healthcare | OPTISON | albumin human | INJECTABLE;INJECTION | 020899-001 | Dec 31, 1997 | ➤ Sign Up | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
International Patents for OPTISON
Supplementary Protection Certificates for OPTISON
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 00673 | Netherlands | ➤ Sign Up | PRODUCT NAME: PACLITAXEL, GEFORMULEERD ALS ALBUMINE-GEBONDEN NANODEELTJES; REGISTRATION NO/DATE: EU/1/07/428/001-002 20131220 |
| 0961612/01 | Switzerland | ➤ Sign Up | PRODUCT NAME: PACLITAXELUM-ALBUMINUM; REGISTRATION NO/DATE: SWISSMEDIC 63182 26.08.2014 |
| /2014 | Austria | ➤ Sign Up | PRODUCT NAME: PACLITAXEL, DAS ALS ALBUMIN GEBUNDENE NANOPARTIKEL FORMUIERT IST.; REGISTRATION NO/DATE: EU/1/07/428 (MITTEILUNG) (GEAENDERT DURCH C(2013) 9835) 20131230 |
| 2009 00036 | Denmark | ➤ Sign Up | PRODUCT NAME: PACLITAXELALBUMIN |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
